Cancer Staging Manual

The AJCC has created a set of desk reference resource materials designed to provide in-depth, easy-to-access information for doctors and other medical professionals staging cancer patients, and for cancer registrars abstracting cancer cases.

Cancer Staging Manual

The AJCC has created a set of desk reference resource materials designed to provide in-depth information for doctors, medical professionals staging cancer patients, and cancer registrars abstracting cancer cases. ​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​

 

  AJCC Cancer Staging Manual, 8th Edition

 

9783319406176.jpg

The AJCC Cancer Staging Manual, 8th Edition is available for purchase. 


Significantly expanded and developed by international disease site expert panels, the Eighth Edition AJCC Cancer Staging Manual brings t​ogether all the currently available knowledge on staging of cancer at various anatomic sites. In this edition, evidence-based TNM staging is supplemented, as appropriate, by selected molecular markers and newly acquired insights into the molecular underpinnings of cancer. This edition features 12 entirely new staging systems, a wide range of changed or new staging definitions, and a refined emphasis on a personalized-medicine approach.

Purchase Here


 

 

 Publishing History

 
Editions of the AJCC Cancer Staging Manual
 
The publication dates and effective dates for past editions of the AJCC Cancer Staging Manual are:
 
Edition​ ​Publication Year ​Effective Year ​Resources
1​ ​1977 ​1978 AJCC 1st Ed Cancer Staging Manual
​2 ​1983 ​1984 AJCC 2nd Ed Cancer Staging Manual
​3 ​1988 ​1989 AJCC 3rd Ed Cancer Staging Manual
​4 ​1992 ​1993 AJCC 4th Edition Cancer Staging Manual​
​5 ​1997 ​1998 AJCC 5th Ed Cancer Staging Manual
​6 ​2002 ​2003

AJCC 6th Ed Cancer Staging Manual Part 1

AJCC 6th Ed Cancer Staging Manual Part 2

​7 ​2009 ​2010 AJCC 7th Ed Cancer Staging Manual
​8 ​2016  ​2018
Purchase Here
 
 

 Errata

 

This list contains important errata identified in the first printing of the AJCC Cancer Staging Manual, 8th Edition, and is effective for hard copy manuals purchased from September 2016 to present.  This list includes errors of omission and only critical errata that affect the meaning of a cancer staging system. Errata are tracked by staff and updated weekly. If you have identified an erratum not listed here, please email laurameyer@facs.org.  

If you would like to receive this information in a spreadsheet, please join our errata mailing list . 

Date Updated

Chapter or Part No.

Chapter or Part Title

Section

Page

Column

Before Correction

After Correction

3/10/2017

81

Primary Cutaneous Lymphomas

Peripheral Blood Involvement (B)

970

2

B0: Absence of significant blood involvement: ≥5% of peripheral blood lymphocytes are atypical (Sézary) cells*

B0: Absence of significant blood involvement: 5% of peripheral blood lymphocytes are atypical (Sézary) cells*

3/3/2017

29

Neuroendocrine Tumors of the Stomach

AJCC Prognostic Stage Groups

355

2

No stage group for TX,T0…

Insert row above T1   N0   M0   I:
TX, T0   NX, N0, N1   M1   IV

3/3/2017

29

Neuroendocrine Tumors of the Stomach

AJCC Prognostic Stage Groups

355

2

T1   N0, N1   M1   IV

T1   NX, N0, N1   M1   IV

3/3/2017

29

Neuroendocrine Tumors of the Stomach

AJCC Prognostic Stage Groups

355

2

T2   N0, N1   M1   IV

T2   NX, N0, N1   M1   IV

3/3/2017

29

Neuroendocrine Tumors of the Stomach

AJCC Prognostic Stage Groups

355

2

T3   N0, N1   M1   IV

T3   NX, N0, N1   M1   IV

3/3/2017

29

Neuroendocrine Tumors of the Stomach

AJCC Prognostic Stage Groups

355

2

T4   N0, N1   M1   IV

T4   NX, N0, N1   M1   IV

3/3/2017

31

Neuroendocrine Tumors of the Jejunum and Ileum

AJCC Prognostic Stage Groups

380

1

No stage group for TX,T0…

Insert row above T1   N0   M0   I:
TX, T0   NX, N0, N1, N2   M1   IV

3/3/2017

31

Neuroendocrine Tumors of the Jejunum and Ileum

AJCC Prognostic Stage Groups

380

1

T1   N0, N1, N2   M1   IV

T1   NX, N0, N1, N2   M1   IV

3/3/2017

31

Neuroendocrine Tumors of the Jejunum and Ileum

AJCC Prognostic Stage Groups

380

1

T2   N0, N1, N2   M1   IV

T2   NX, N0, N1, N2   M1   IV

3/3/2017

31

Neuroendocrine Tumors of the Jejunum and Ileum

AJCC Prognostic Stage Groups

380

1

T3   N0, N1, N2   M1   IV

T3   NX, N0, N1, N2   M1   IV

3/3/2017

31

Neuroendocrine Tumors of the Jejunum and Ileum

AJCC Prognostic Stage Groups

380

1

T4   N0, N1, N2   M1   IV

T4   NX, N0, N1, N2   M1   IV

3/3/2017

32

Neuroendocrine Tumors of the Appendix

AJCC Prognostic Stage Groups

392

2

No stage group for TX,T0…

Insert row above T1   N0   M0   I:
TX, T0   NX, N0, N1   M1   IV

3/3/2017

32

Neuroendocrine Tumors of the Appendix

AJCC Prognostic Stage Groups

392

2

T1   N0, N1   M1   IV

T1   NX, N0, N1   M1   IV

3/3/2017

32

Neuroendocrine Tumors of the Appendix

AJCC Prognostic Stage Groups

392

2

T2   N0, N1   M1   IV

T2   NX, N0, N1   M1   IV

3/3/2017

32

Neuroendocrine Tumors of the Appendix

AJCC Prognostic Stage Groups

392

2

T3   N0, N1   M1   IV

T3   NX, N0, N1   M1   IV

3/3/2017

32

Neuroendocrine Tumors of the Appendix

AJCC Prognostic Stage Groups

392

2

T4   N0, N1   M1   IV

T4   NX, N0, N1   M1   IV

3/3/2017

33

Neuroendocrine Tumors of the Colon and Rectum

AJCC Prognostic Stage Groups

399

2

No stage group for TX,T0…

Insert row above T1   N0   M0   I:
TX, T0   Any N   M1   IV

2/24/2017

55

Ovary, Fallopian Tube and Primary Peritoneal Carcinoma

Anatomy

685

1

Heading: Regional Lymph Nodes

Heading: Metastatic Sites

2/24/2017

55

Ovary, Fallopian Tube and Primary Peritoneal Carcinoma

Fig. 55.2

684

2

Inguinal

Inguinal (distant, M1b)

2/10/2017

Front Matter

Preface

n/a

ix

n/a

…effective for all cases diagnosed on or after January 1, 2017.

…effective for all cases diagnosed on or after January 1, 2018.

2/10/2017

1

Principles of Cancer Staging

Philosophy of Revisions to the TNM Staging System

3

2

…effective for cancer patients diagnosed on or after January 1, 2017.

…effective for cancer patients diagnosed on or after January 1, 2018.

2/10/2017

1

Principles of Cancer Staging

Table 1.1

4

1

2010-2016

2010-2017

2/10/2017

1

Principles of Cancer Staging

Table 1.1

4

1

2017

2018

2/10/2017

2

Organization of the AJCC Cancer Staging Manual

Developing the 8th Edition Project Plan

31

2

…adopted for application to cases diagnosed on or after January 1, 2017

…adopted for application to cases diagnosed on or after January 1, 2018

2/10/2017

19

Appendix - Carcinoma

WHO Classification of Tumors

238

1

8073 Squamous cell carcinoma

8070 Squamous cell carcinoma, NOS

2/10/2017

37

Malignant Pleural Mesothelioma

Definition of Primary Tumor (T)

465

2

T1 Tumor limited to the ipsilateral parietal with or without involvement of

T1 Tumor limited to the ipsilateral parietal pleura with or without involvement of

2/3/2017

82

Plasma Cell Myeloma and Plasma Cell Disorders

Author List

973

n/a

P. Leif Bergsagel, Elaine S. Jaffe, John P. Leonard

P. Leif Bergsagel, Vincent Rajkumar, Ola Landgren, Michael M. Graham, Joseph Khoury, Elaine S. Jaffe, John P. Leonard

1/27/2017

64

Eyelid Carcinoma

AJCC Prognostic Stage Groups

783

2

T2b-d, T3; N0; M0; IIA

T2b-c, T3; N0; M0; IIA

1/27/2017

67

Uveal Melanoma

Definition of Primary Tumor (T) - Iris Melanomas

812

1

No TX or T0 categories and criteria in table.

TX: Primary tumor cannot be assessed
T0: No evidence of primary tumor

1/27/2017

67

Uveal Melanoma

Definition of Primary Tumor (T) - Choroidal and Ciliary Body Melanomas

812

2

No TX or T0 categories and criteria in table.

TX: Primary tumor cannot be assessed
T0: No evidence of primary tumor

1/6/2017

5

Staging Head and Neck Cancers

Pathological N (pN)

61

1

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(−)

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph node
(s), none larger than 6 cm in greatest dimension, ENE(−)

1/6/2017

5

Staging Head and Neck Cancers

Pathological N (pN)

61

1

N2a: Metastasis in single ipsilateral or contralateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

N2a: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

5

Staging Head and Neck Cancers

Pathological N (pN)

61

1

N2c: Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−)

N2c: Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

5

Staging Head and Neck Cancers

Pathological N (pN)

61

2

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−)
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+)
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+)
;
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

5

Staging Head and Neck Cancers

Pathological N (pN)

61

2

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+)
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

5

Staging Head and Neck Cancers

Clinical N (cN)

61

1

N2a: Metastasis in single ipsilateral or contralateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

N2a: Metastasis in single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

5

Staging Head and Neck Cancers

Clinical N (cN)

61

1

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node ENE(+)
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in any lymph node(s) with clinically overt ENE(+)

1/6/2017

5

Staging Head and Neck Cancers

Clinical N (cN)

61

1

N3b: Metastasis in a single ipsilateral node ENE(+)
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3b: Metastasis in any lymph node(s) with clinically overt ENE(+)

1/6/2017

6

Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck

Pathological N (pN)

75

1

N2: Metastasis in a single ipsilateral or contralateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or
single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph node
(s), none larger than 6 cm

1/6/2017

6

Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck

Pathological N (pN)

75

1

N2a: Metastasis in single ipsilateral or contralateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

N2a: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

6

Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck

Pathological N (pN)

75

1

N2c: Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−)

N2c: Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

6

Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck

Pathological N (pN)

75

1

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−)
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+)
or multiple ipsilateral, contralateral, or bilateral nodes in any size with ENE(+) in any node

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−)
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+)
or multiple ipsilateral, contralateral, or bilateral nodes in any size with ENE(+) in any node
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

6

Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck

Pathological N (pN)

75

1

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes any size and ENE(+) in any node

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes any size and ENE(+) in any node
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

7

Lip and Oral Cavity

Pathological N (pN)

91

1

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(−)

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph node
(s), none larger than 6 cm in greatest dimension, ENE(−)

1/6/2017

7

Lip and Oral Cavity

Pathological N (pN)

91

1

N2a: Metastasis in single ipsilateral or contralateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

N2a: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

7

Lip and Oral Cavity

Pathological N (pN)

91

1

N2c: Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−)

N2c: Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

7

Lip and Oral Cavity

Pathological N (pN)

91

1

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE
(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

7

Lip and Oral Cavity

Pathological N (pN)

91

1

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+)
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

7

Lip and Oral Cavity

Mucosal Lip

81

2

The remander of the vermillion is staged using the skin chapter (Chapter 47).

The remander of the vermillion is stage using the chapter on cutaneous squamous cell carcinoma of the head and neck (Chapter 15).

1/6/2017

8

Major Salivary Glands

Pathological N (pN)

100

1

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(−)

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph node
(s), none larger than 6 cm in greatest dimension, ENE(−)

1/6/2017

8

Major Salivary Glands

Pathological N (pN)

100

1

N2a: Metastasis in single ipsilateral or contralateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

N2a: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

8

Major Salivary Glands

Pathological N (pN)

100

2

N2c: Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−)

N2c: Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

8

Major Salivary Glands

Pathological N (pN)

100

2

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE
(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

8

Major Salivary Glands

Pathological N (pN)

100

2

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+)
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

11

Oropharynx (p16-) and Hypopharynx

Pathological N (pN)

129

2

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(−)

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph node
(s), none larger than 6 cm in greatest dimension, ENE(−)

1/6/2017

11

Oropharynx (p16-) and Hypopharynx

Pathological N (pN)

129

2

N2a: Metastasis in single ipsilateral or contralateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

N2a: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

11

Oropharynx (p16-) and Hypopharynx

Pathological N (pN)

129

2

N2c: Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−)

N2c: Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

11

Oropharynx (p16-) and Hypopharynx

Pathological N (pN)

129

2

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE
(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

11

Oropharynx (p16-) and Hypopharynx

Pathological N (pN)

129

2

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+)
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

12

Nasal Cavity and Paranasal Sinuses

Pathological N (pN)

143

1

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(−)

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph node
(s), none larger than 6 cm in greatest dimension, ENE(−)

1/6/2017

12

Nasal Cavity and Paranasal Sinuses

Pathological N (pN)

143

1

N2a: Metastasis in single ipsilateral or contralateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

N2a: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

12

Nasal Cavity and Paranasal Sinuses

Pathological N (pN)

143

1

N2c: Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−)

N2c: Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

12

Nasal Cavity and Paranasal Sinuses

Pathological N (pN)

143

1

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE
(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

12

Nasal Cavity and Paranasal Sinuses

Pathological N (pN)

143

1

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+)
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

13

Larynx

Pathological N (pN)

156

1

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(−)

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph node
(s), none larger than 6 cm in greatest dimension, ENE(−)

1/6/2017

13

Larynx

Pathological N (pN)

156

1

N2a: Metastasis in single ipsilateral or contralateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

N2a: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

13

Larynx

Pathological N (pN)

156

1

N2c: Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−)

N2c: Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

13

Larynx

Pathological N (pN)

156

1

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE
(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

13

Larynx

Pathological N (pN)

156

1

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+)
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

14

Cutaneous Squamous Cell Carcinoma of the Head and Neck

Pathological N (pN)

178

2

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(−)

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph node
(s), none larger than 6 cm in greatest dimension, ENE(−)

1/6/2017

14

Cutaneous Squamous Cell Carcinoma of the Head and Neck

Pathological N (pN)

178

2

N2a: Metastasis in single ipsilateral or contralateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

N2a: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

14

Cutaneous Squamous Cell Carcinoma of the Head and Neck

Pathological N (pN)

178

2

N2c: Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−)

N2c: Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

14

Cutaneous Squamous Cell Carcinoma of the Head and Neck

Pathological N (pN)

178

2

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE
(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

14

Cutaneous Squamous Cell Carcinoma of the Head and Neck

Pathological N (pN)

178

2

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+)
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

19

Appendix - Carcinoma

AJCC Prognostic Stage Groups

243

2

Any T, N0, M1a, IVA

Any T, Any N, M1a, IVA

1/6/2017

50

Vulva

Definition of Regional Lymph Node (N)

637

1

N1, N1b, N2, N2b Criteria: "=5 mm"

N1, N1b, N2, N2b Criteria: "greater than or equal to 5 mm"

1/6/2017

66

Conjunctival Melanoma

Definition of Primary Tumor (T)

799

2

T4: Tumor of any size with invasion of the paranasal sinuses and/or central nervous system

T4: Tumor of any size with invasion of the central nervous system

1/6/2017

67

Uveal Melanoma

Definition of Regional Lymph Node (N)

813

1

N1b: No regional lymph nodes are positive, but there are discrete tumor deposits in the orbit that are not contiguous to the eye.

N1b: No regional lymph nodes are positive, but there are discrete tumor deposits in the orbit that are not contiguous to the eye. (choroidal and ciliary body)

12/16/2016

15

Cutaneous Squamous Cell Carcinoma of the Head and Neck

Definition of Primary Tumor (T)

178

1

TX: Primary tumor cannot be identified

TX: Primary tumor cannot be assessed

12/16/2016

55

Ovary, Fallopian Tube and Primary Peritoneal Carcinoma

Definition of Primary Tumor (T)

688

1

T1a (FIGO Stage IA): Tumor limited to one ovary (capsule intact) or fallopian tube surface; no malignant cells in ascites or peritoneal washings

T1a (FIGO Stage IA) Tumor limited to one ovary (capsule intact) or fallopian tube, no tumor on ovarian or fallopian tube surface; no malignant cells in ascites or peritoneal washings

12/16/2016

55

Ovary, Fallopian Tube and Primary Peritoneal Carcinoma

Definition of Primary Tumor (T)

688

1

T1b (FIGO Stage IB): Tumor limited to one or both ovaries (capsules intact) or fallopian tubes; no tumor on ovarian or fallopian tube surface; no malignant cells in ascites or peritoneal washings

T1b (FIGO Stage IB): Tumor limited to both ovaries (capsules intact) or fallopian tubes; no tumor on ovarian or fallopian tube surface; no malignant cells in ascites or peritoneal washings

12/16/2016

55

Ovary, Fallopian Tube and Primary Peritoneal Carcinoma

Definition of Regional Lymph Node (N)

688

2

N1a (FIGO Stage IIIA1i) Metastasis up to 10 mm in greatest dimension

N1a (FIGO Stage IIIA1i) Metastasis up to and including 10 mm in greatest dimension

12/16/2016

79

Hodgkin and Non-Hodgkin Lymphoma

AJCC Prognostic Stage Groups

954

2

IV: Stage IV includes any involvement of the CSF, bone marrow, liver, or lungs (other than by direct extension in IIE disease).

IV: Stage IV includes any involvement of the CSF, bone marrow, liver, or multiple lung lesions (other than by direct extension in IIE disease).

12/16/2016

80

Pediatric Hodgkin Lymphoma

AJCC Prognostic Stage Groups

964

1

IV: Stage IV includes any involvement of the CSF, bone marrow, liver, or lungs (other than by direct extension in IIE disease).

IV: Stage IV includes any involvement of the CSF, bone marrow, liver, or multiple lung lesions (other than by direct extension in IIE disease).

12/9/2016

7

Lip and Oral Cavity

AJCC Prognostic Stage Groups

91

2

No stage 0

insert row above T1   N0   M0  I:
Tis   N0   M0   0

12/9/2016

7

Lip and Oral Cavity

Rules for Classification > Pathological Classification > Pathological assessment of ENE

85

1

Only ENEma is used to define pathological ENE(+) nodal status

ENEmi and ENEma are used to define pathological ENE(+) nodal status

12/9/2016

7

Lip and Oral Cavity

Rules for Classification > Pathological Classification > Pathological assessment of ENE

85

1

Only ENEma is used to define pathological ENE nodal status (Fig. 7.5). ENEmi versus ENEn will not affect current nodal staging, but data collection is recommended to allow standardization of data collection and future analysis.

ENEmi and ENEma are used to define pathological ENE nodal status (Fig. 7.5). ENEmi versus ENEn will affect current nodal staging, and data collection is recommended to allow standardization of data collection and future analysis.

12/9/2016

9

Nasopharynx

Definition of Primary Tumor (T)

107

2

No definition for Tis

Tis: Carcinoma in situ (insert row between T0 and T1)

12/9/2016

16

Esophagus and Esophagogastric Junction

Anatomy

187

n/a

Table 16.1 Primary site of esophageal cancer based on proximal edge of tumor

Table 16.1 Anatomy of esophageal cancer primary site by ICD-O-3 topography codes

12/9/2016

38

Bone

WHO Classification of Tumors

472

2

8540 Malignant peripheral nerve sheath tumor

9540 Malignant peripheral nerve sheath tumor

12/9/2016

55

Ovary, Fallopian Tube and Primary Peritoneal Carcinoma

WHO Classification of Tumors

682

1

8260 Adult granulosa cell tumor

8620 Adult granulosa cell tumor

12/9/2016

55

Ovary, Fallopian Tube and Primary Peritoneal Carcinoma

WHO Classification of Tumors

682

1

8542 Solid pseudopapillary neoplasm

8452 Solid pseudopapillary neoplasm

12/9/2016

55

Ovary, Fallopian Tube and Primary Peritoneal Carcinoma

WHO Classification of Tumors

682

1

8960 Paraganglioma

8960 Wilms tumor

12/9/2016

55

Ovary, Fallopian Tube and Primary Peritoneal Carcinoma

WHO Classification of Tumors

682

1

8963 Extra-gastrointestinal stromal tumor

8936 Extra-gastrointestinal stromal tumor

12/2/2016

54

Corpus Uteri - Sarcoma

AJCC Prognostic Stage Groups

675

2

Incorrect table title: Leiomyosarcoma and Endometrial Stromal Sarcoma

Correct table title: Adenosarcoma

12/2/2016

54

Corpus Uteri - Sarcoma

AJCC Prognostic Stage Groups

675

2

Incorrect table title: Adenosarcoma

Correct table title: Leiomyosarcoma and Endometrial Stromal Sarcoma

12/2/2016

62

Urinary Bladder

AJCC Prognostic Stage Groups

764

1

T4b N0 M0 IVA

T4b Any N M0 IVA

12/2/2016

74

Thyroid - Medullary

Prognostic Factors > Additional Factors Recommended for Clinical Care

896

2

Incorrect heading: Sporadic or Medullary MTC

Sporadic or Hereditary MTC

11/18/2016

All

All

n/a

n/a

n/a

Effective date for 8th Edition staging rules: January 1, 2017

Effective date for 8th Edition staging rules: January 1, 2018

11/18/2016

73

Thyroid - Differentiated and Anaplastic

WHO Classification of Tumors

874

1

Code omitted

8260 Papillary carcinoma of the thyroid

11/18/2016

73

Thyroid - Differentiated and Anaplastic

WHO Classification of Tumors

874

1

8050 Papillary carcinoma

8050 Papillary carcinoma, NOS

11/11/2016

12

Nasal Cavity and Paranasal Sinuses

WHO Classification of Tumors

138

1

8429 Atypical Carcinoid

8249 Atypical Carcinoid

11/11/2016

67

Uveal Melanoma

Definition of Regional Lymph Node (N)

812

2

No definition for NX and N0

NX     Regional lymph nodes cannot be assessed
N0     No regional lymph node involvement

11/11/2016

68

Retinoblastoma

AJCC Prognostic Stage Groups

826

1, 2

 

Add T, N or H after Any in the clinical and pathological stage tables.

11/11/2016

71

Ocular Adnexal Lymphoma

Definition of Distant Metastasis (M)

852

1

No definition for M1

M1: Evidence of involvement of other extranodal sites

11/4/2016

II

Head and Neck

Members of the Head and Neck Expert Panel

53

1

Panel member name omitted

Shirley Jordan Seay, PhD, OCN, CTR - Data Collection Core Representative

11/4/2016

58

Prostate

AJCC Prognostic Stage Groups

724

2

Any T, N0, M1, Any PSA, Any G, IVB

Any T, Any N, M1, Any PSA, Any G, IVB

10/28/2016

52

Cervix Uteri

Author List

649

n/a

…Ian S. Hagemann, Esther Oliva, Lorraine Portelance…

…Ian S. Hageman, Lorraine Portelance…

10/28/2016

54

Corpus Uteri - Sarcoma

Author List

671

n/a

…Ian S. Hagemann, Matthew A. Powell…

...Ian S. Hagemann, Esther Oliva, Matthew A. Powell…

10/28/2016

55

Ovary, Fallopian Tube and Primary Peritoneal Carcinoma

AJCC Prognostic Stage Groups

688

2

When T is T3a, T3b, T3c, N is N0, N1

When T is T3a, T3b, T3c, N is NX, N0, N1

10/28/2016

58

Prostate

Definition of Histologic Grade Group

724

1

Grade Group 4, Gleason Score 8, Gleason Pattern 4+4

Grade Group 4, Gleason Score 8, Gleason Pattern 4+4, 3+5, 5+3

10/28/2016

58

Prostate

AJCC Prognostic Stage Groups

724

2

cT1a-c, cT2a N0 M0 PSA≥ 10 < 20 G1 IIA

cT1a-c, cT2a, pT2 N0 M0 PSA≥ 10 < 20 G1 IIA

10/28/2016

60

Kidney

AJCC Prognostic Stage Groups

744

1

T3    N0     M0     III

T3    NX, N0    M0   III

10/28/2016

61

Renal Pelvis and Ureter

AJCC Prognostic Stage Groups

754

1

T4 N0 M0 Stage IV

T4 NX, N0 M0 Stage IV

10/28/2016

73

Thyroid - Differentiated and Anaplastic

Imaging

877

2

Most patients will be clinical MX, as routine use of cross-sectional or functional (RAI)…

Most patients will be clinical M0, as routine use of cross-sectional or functional (RAI)…